Cargando…
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hampe...
Autores principales: | Iaffaioli, R V, Formato, R, Tortoriello, A, Prete, S Del, Caraglia, M, Pappagallo, G, Pisano, A, Fanelli, F, Ianniello, G, Cigolari, S, Pizza, C, Marano, O, Pezzella, G, Pedicini, T, Febbraro, A, Incoronato, P, Manzione, L, Ferrari, E, Marzano, N, Quattrin, S, Pisconti, S, Nasti, G, Giotta, G, Colucci, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362023/ https://www.ncbi.nlm.nih.gov/pubmed/15856035 http://dx.doi.org/10.1038/sj.bjc.6602579 |
Ejemplares similares
-
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005) -
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021) -
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020) -
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
por: Riccardi, Ferdinando, et al.
Publicado: (2018) -
Supportive care in patients with advanced non-small-cell lung cancer
por: Di Maio, M, et al.
Publicado: (2003)